Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Pacira BioSciences, Inc. (PCRX)
Price$23.95Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $418.9M | $332.4M | $284.3M | $270.1M | $249.0M | $197.7M | $85.6M | $39.1M | $15.7M | $14.6M | $15.0M |
| Gross profit | $576.7M | $530.5M | $490.3M | $467.5M | $401.3M | $312.3M | $312.2M | $245.6M | $196.4M | $160.0M | $177.2M | $120.2M | $30.8M | $6.9M | −$1.1M | $2.3M | $2.7M |
| Gross margin | 79.39% | 75.69% | 72.64% | 70.11% | 74.10% | 72.69% | 74.53% | 73.88% | 69.08% | 59.23% | 71.15% | 60.82% | 35.98% | 17.77% | −6.69% | 15.70% | 18.03% |
| Research & development | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M | $59.4M | $72.1M | $55.7M | $57.3M | $45.7M | $28.7M | $18.7M | $21.6M | $9.9M | $14.9M | $18.6M | $26.2M |
| Operating expenses | $707.2M | $774.3M | $587.3M | $606.8M | $451.6M | $383.3M | $410.5M | $321.4M | $311.6M | $308.4M | $239.5M | $202.8M | $138.8M | $88.4M | $54.8M | $37.3M | $43.6M |
| Operating income | $19.2M | −$73.4M | $87.7M | $60.0M | $89.9M | $46.4M | $10.5M | $15.9M | −$24.9M | −$32.0M | $9.5M | −$5.2M | −$53.3M | −$49.3M | −$39.1M | −$22.7M | −$28.5M |
| Operating margin | 2.64% | −10.47% | 12.99% | 9.00% | 16.61% | 10.79% | 2.50% | 4.79% | −8.77% | −11.86% | 3.80% | −2.61% | −62.29% | −126.13% | −249.23% | −155.95% | −190.24% |
| EBITDA | $110.2M | $5.4M | $163.2M | $151.5M | $118.5M | $66.3M | $30.1M | $29.1M | −$11.1M | −$19.1M | $20.9M | $4.9M | −$47.5M | −$43.6M | −$34.8M | −$18.6M | −$24.4M |
| EBITDA margin | 15.17% | 0.77% | 24.19% | 22.72% | 21.88% | 15.42% | 7.17% | 8.75% | −3.91% | −7.07% | 8.41% | 2.46% | −55.57% | −111.68% | −221.73% | −127.99% | −162.61% |
| Net income | $7.0M | −$99.6M | $42.0M | $15.9M | $42.0M | $145.5M | −$11.0M | −$471,000 | −$42.6M | −$37.9M | $1.9M | −$13.7M | −$63.9M | −$52.3M | −$43.3M | −$27.1M | −$31.7M |
| Net profit margin | 0.97% | −14.20% | 6.22% | 2.39% | 7.75% | 33.87% | −2.63% | −0.14% | −14.99% | −14.05% | 0.75% | −6.94% | −74.70% | −133.77% | −276.17% | −186.44% | −211.30% |
| Basic EPSper basic share | $0.16 | -$2.15 | $0.91 | $0.35 | $0.95 | $3.41 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.05 | -$0.39 | -$1.93 | -$1.72 | -$2.64 | -$47.29 | -$55.32 |
| Diluted EPSper diluted share | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 | $3.33 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.04 | -$0.39 | -$1.93 | -$1.72 | -$2.64 | -$47.29 | -$55.32 |
Owners
Reported shareholders
16.84%of listed shares
BlackRock, Inc.6.71M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 16.84%6.71M shares |
Doma Perpetual Capital Management LLC | 6.98%2.78M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 6.04%2.41M shares |
DIMENSIONAL FUND ADVISORS LP | 5.28%2.1M shares |
STATE STREET CORP | 5.17%2.06M shares |
D. E. Shaw & Co., Inc. | 4.90%1.95M shares |
RENAISSANCE TECHNOLOGIES LLC | 4.35%1.73M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.25%1.69M shares |
GOLDMAN SACHS GROUP INC | 3.83%1.53M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.91%1.16M shares |
MORGAN STANLEY | 2.87%1.14M shares |
AMERICAN CENTURY COMPANIES INC | 2.56%1.02M shares |
UBS Group AG | 2.31%920.22K shares |
Impax Asset Management Group plc | 1.88%750.03K shares |
TWO SIGMA INVESTMENTS, LP | 1.82%724.6K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.73%690.79K shares |
Lee Frank D. | ≈1.66%660.83K shares |
GAGNON SECURITIES LLC | 1.53%608.62K shares |
LSV ASSET MANAGEMENT | 1.53%608.38K shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.41%563.46K shares |
Percentages use 39.82M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 · 10b5-1 | RIKER LAURENSenior Vice President, Finance | SellCommon Stock | 6.1K | $23.50 | $143.7K | 62.3K |
| Jun 4, 2026Form 4 · 10b5-1 | WILLIAMS KRISTENChief Administrative Officer | SellCommon Stock | 10.3K | $22.27 | $228.5K | 167.1K |
| Apr 23, 2026Form 4 · 10b5-1 | Cross ShawnChief Financial Officer | SellCommon Stock | 12.9K | $25.16 | $325.6K | 105.3K |
| Apr 22, 2026Form 4 · 10b5-1 | Cross ShawnChief Financial Officer | SellCommon Stock | 1.5K | $25.01 | $37.5K | 105.3K |
| Apr 21, 2026Form 4 · 10b5-1 | Cross ShawnChief Financial Officer | SellCommon Stock | 2.8K | $25.01 | $71.2K | 105.3K |